We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Thalassemia - Pipeline Review, H2 2018

Published: August 2018
Pages: 164
Code: 08C767FE68732045F1BCEFD00F19C865
Format: PDF
Publisher Global Markets Direct
From Add to basket
$ 2,000.00
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide , provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.
Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide , provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 10, 7, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 1 molecules, respectively.
Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Additonal Information

  • - The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).
  • - The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • - The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • - The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • - The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)

Companies Mentioned

Acceleron Pharma Inc
Agios Pharmaceuticals Inc
bluebird bio Inc
Cadila Healthcare Ltd
Calimmune Inc
CRISPR Therapeutics
Editas Medicine Inc
Errant Gene Therapeutics LLC
Gamida Cell Ltd
Gilead Sciences Inc
Incyte Corp
Ionis Pharmaceuticals Inc
Kiadis Pharma NV
La Jolla Pharmaceutical Company
Merck & Co Inc
Poseida Therapeutics Inc
Protagonist Therapeutics Inc
Sangamo Therapeutics Inc
Silence Therapeutics Plc
Vifor Pharma AG

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics. Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.
Add to basket
  • Table of Contents
  • Table of Contents 2
  • Introduction 5
  • Thalassemia - Overview 6
  • Thalassemia - Therapeutics Development 7
  • Thalassemia - Therapeutics Assessment 15
  • Thalassemia - Companies Involved in Therapeutics Development 25
  • Thalassemia - Drug Profiles 35
  • Thalassemia - Dormant Projects 143
  • Thalassemia - Discontinued Products 144
  • Thalassemia - Product Development Milestones 145
  • Appendix 158
  • List of Tables
  • Number of Products under Development for Thalassemia, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Thalassemia - Pipeline by Acceleron Pharma Inc, H2 2018
  • Thalassemia - Pipeline by Agios Pharmaceuticals Inc, H2 2018
  • Thalassemia - Pipeline by bluebird bio Inc, H2 2018
  • Thalassemia - Pipeline by Cadila Healthcare Ltd, H2 2018
  • Thalassemia - Pipeline by Calimmune Inc, H2 2018
  • Thalassemia - Pipeline by CRISPR Therapeutics, H2 2018
  • Thalassemia - Pipeline by Editas Medicine Inc, H2 2018
  • Thalassemia - Pipeline by Errant Gene Therapeutics LLC, H2 2018
  • Thalassemia - Pipeline by Gamida Cell Ltd, H2 2018
  • Thalassemia - Pipeline by Gilead Sciences Inc, H2 2018
  • Thalassemia - Pipeline by Incyte Corp, H2 2018
  • Thalassemia - Pipeline by Ionis Pharmaceuticals Inc, H2 2018
  • Thalassemia - Pipeline by Kiadis Pharma NV, H2 2018
  • Thalassemia - Pipeline by La Jolla Pharmaceutical Company, H2 2018
  • Thalassemia - Pipeline by Merck & Co Inc, H2 2018
  • Thalassemia - Pipeline by Poseida Therapeutics Inc, H2 2018
  • Thalassemia - Pipeline by Protagonist Therapeutics Inc, H2 2018
  • Thalassemia - Pipeline by Sangamo Therapeutics Inc, H2 2018
  • Thalassemia - Pipeline by Silence Therapeutics Plc, H2 2018
  • Thalassemia - Pipeline by Vifor Pharma AG, H2 2018
  • Thalassemia - Dormant Projects, H2 2018
  • Thalassemia - Discontinued Products, H2 2018
  • List of Figures
  • Number of Products under Development for Thalassemia, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

Keywords
;